IceCure Medical’s IceSense3 Cryoprobes Approved in China

March 28, 2023—IceCure Medical Ltd., an Israel-based developer of the minimally invasive liquid nitrogen–based ProSense system cryoablation technology, which is marketed in China as IceSense3, announced the National Medical Products Administration (NMPA) of China approved the IceSense3 disposable cryoprobes for commercial use. The cryoprobes are to be used in combination with the company’s IceSense3 console, which was previously approved by the NMPA.

With this latest approval, the technology can be used in China to treat malignant and benign tissue of the breast, lung, bone, liver, and kidneys, as well as palliative interventions. The technology destroys tumors by freezing as an alternative to surgical tumor removal.

The IceSense3 system will be distributed in China through an agreement with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc, and Beijing Turing Medical Technology Co. Ltd.

Eyal Shamir, IceCure’s Chief Executive Officer, commented in the company’s press release, “With approximately 430,000 new breast cancer cases in 2022 alone, and a health care system readily adopting new technologies that produce improved outcomes, we see China as a prime market for our cryoablation system. Having received regulatory approval for commercial sales of both our console and cryoprobes, we expect to effectively monetize our distribution agreement in the Chinese market.”

IceCure Medical’s markets ProSense worldwide for the indications cleared to date by the FDA and approved with the European CE Mark in Europe. ProSense is a liquid-nitrogen-based cryoablation therapy for the treatment of benign and cancerous tumors by freezing.